Clinical update on palonosetron in the management of chemotherapy-induced nausea and vomiting

被引:1
作者
Celio, Luigi [1 ]
Denaro, Angela [1 ]
Canova, Stefania [1 ]
Gevorgyan, Arpine [1 ]
Bajetta, Emilio [1 ]
机构
[1] Ist Nazl Tumori, Fdn IRCCS, Med Oncol Unit 2, I-20133 Milan, Italy
来源
TUMORI JOURNAL | 2008年 / 94卷 / 04期
关键词
antagonist; antiemetics; chemotherapy-induced nausea and vomiting; palonosetron;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The need to control chemotherapy-induced nausea and vomiting is continuously stimulating research to find better options for the optimal antiemetic care. Palonosetron is different from conventional serotonin receptor antagonists not only by the fact of having a longer half-life but also by higher binding affinity for serotonin receptors. It is the first agent in the class which is approved for preventing both delayed and acute emesis induced by moderately emetogenic chemotherapy. Recent studies using palonosetron-based antiemetic regimens, as well as in the clinical setting of multiple-day chemotherapy, have been reported. Palonosetron plus dexamethasone given as a pre-treatment infusion was effective for preventing acute and delayed emesis after moderately emetogenic chemotherapy. Palonosetron in combination with dexamethasone and aprepitant was highly effective in preventing emesis in the days following administration of moderately emetogenic chemotherapy. Treatment was well tolerated, with no unexpected adverse events. Multiple-day dosing of palonosetron plus dexamethasone was safe and effective for prevention of emesis induced by 5-day cisplatin-based chemotherapy. There was no evidence of cumulative toxicity when palonosetron was given three times over 5 days. Further evidence from ongoing clinical trials with palonosetron with or without dexamethasone will be available soon. Palonosetron represents an useful addition to the therapeutic armamentarium for the management of chemotherapy-induced nausea and vomiting. Further studies are needed to assess the effectiveness of palonosetron in combination with dexamethasone compared with that of older serotonin receptor antagonists combined with dexamethasone. However, palonosetron may offer advantages of convenience over the short-acting older antagonists due to its ability to be given as a single intravenous dose prior to chemotherapy.
引用
收藏
页码:447 / 452
页数:6
相关论文
共 50 条
  • [31] Palonosetron Prevents Highly Emetogenic Chemotherapy-induced Nausea and Vomiting in Oral Cancer Patients
    Sento, Shinya
    Kitamura, Naoya
    Yamamoto, Tetsuya
    Nakashiro, Koichi
    Hamakawa, Hiroyuki
    Ibaragi, Soichiro
    Sasaki, Akira
    Takamaru, Natsumi
    Miyamoto, Yoji
    Kodani, Isamu
    Ryoke, Kazuo
    Mishima, Katsuaki
    Ueyama, Yoshiya
    ANTICANCER RESEARCH, 2017, 37 (12) : 6977 - 6981
  • [32] Palonosetron hydrochloride is an effective and safe option to prevent chemotherapy-induced nausea and vomiting in children
    Sepulveda-Vildosola, Ana Carolina
    Betanzos-Cabrera, Yadira
    Lastiri, Graciela Gascon
    Rivera-Marquez, Hugo
    Villasis-Keever, Miguel Angel
    del Angel, Volkmar Wanzke
    Diaz, Fernando Cerecedo
    Lopez-Aguilar, Enrique
    ARCHIVES OF MEDICAL RESEARCH, 2008, 39 (06) : 601 - 606
  • [33] Chemotherapy-induced nausea and vomiting – standards in 2012
    S. Lorenzen
    memo - Magazine of European Medical Oncology, 2012, 5 (1) : 47 - 51
  • [34] Efficacy of oral palonosetron compared to intravenous palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: a phase 3 trial
    Boccia, Ralph
    Grunberg, Steven
    Franco-Gonzales, Edwin
    Rubenstein, Edward
    Voisin, Daniel
    SUPPORTIVE CARE IN CANCER, 2013, 21 (05) : 1453 - 1460
  • [35] Efficacy of oral palonosetron compared to intravenous palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: a phase 3 trial
    Ralph Boccia
    Steven Grunberg
    Edwin Franco-Gonzales
    Edward Rubenstein
    Daniel Voisin
    Supportive Care in Cancer, 2013, 21 : 1453 - 1460
  • [36] Palonosetron with aprepitant plus dexamethasone to prevent chemotherapy-induced nausea and vomiting during gemcitabine/cisplatin in urothelial cancer patients
    Kitamura, Hiroshi
    Takahashi, Atsushi
    Hotta, Hiroshi
    Kato, Ryuichi
    Kunishima, Yasuharu
    Takei, Fumiyasu
    Horita, Hiroki
    Masumori, Naoya
    INTERNATIONAL JOURNAL OF UROLOGY, 2015, 22 (10) : 911 - 914
  • [37] Chemotherapy-induced nausea and vomiting standards in 2012
    Lorenzen, S.
    MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, 2012, 5 (01) : 47 - 51
  • [38] Palonosetron versus granisetron in combination with aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with gynecologic cancer
    Fujiwara, Satoe
    Terai, Yoshito
    Tsunetoh, Satoshi
    Sasaki, Hiroshi
    Kanemura, Masanori
    Ohmichi, Masahide
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2015, 26 (04) : 311 - 319
  • [39] Neuropharmacology and Management of Chemotherapy-Induced Nausea and Vomiting in Patients with Breast Cancer
    Jordan, Karin
    Schaffrath, Judith
    Jahn, Franziska
    Mueller-Tidow, Carsten
    Jordan, Berit
    BREAST CARE, 2014, 9 (04) : 246 - 253
  • [40] Rolapitant for the treatment of chemotherapy-induced nausea and vomiting: a review of the clinical evidence
    Chasen, Martin R.
    Rapoport, Bernardo L.
    FUTURE ONCOLOGY, 2016, 12 (06) : 763 - 778